Tarsus Pharmaceuticals, Inc. TARS Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s pre-tax income?
- Tarsus Pharmaceuticals, Inc. (TARS) reported pre-tax income of -$16.09M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s pre-tax income increased by 44.3% year-over-year, from -$28.89M to -$16.09M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s pre-tax income?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s pre-tax income has grown at a 47.0% compound annual growth rate (CAGR), from -$13.77M to -$64.36M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.